PALISADE BIO, INC. Repayments of Long-Term Debt
PALISADE BIO, INC. (PALI) reported Repayments of Long-Term Debt of $3.77 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-22.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2019-03-22
- PALISADE BIO, INC. repayments of long-term debt for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- PALISADE BIO, INC. repayments of long-term debt for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- PALISADE BIO, INC. repayments of long-term debt for the quarter ending 2017-06-30 was $2.54M, a 125.24% increase year-over-year.
- PALISADE BIO, INC. repayments of long-term debt for the quarter ending 2017-03-31 was $1.22M, a 11.45% increase year-over-year.
- PALISADE BIO, INC. repayments of long-term debt for fiscal 2017 was $3.77M, a 17.59% decline from fiscal 2016.
- PALISADE BIO, INC. repayments of long-term debt for fiscal 2016 was $4.57M, a 295.92% increase from fiscal 2015.
- PALISADE BIO, INC. repayments of long-term debt for fiscal 2015 was $1.15M, a 40.18% decline from fiscal 2014.
- PALISADE BIO, INC. repayments of long-term debt for fiscal 2014 was $1.93M.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $0.00 derived: sum of 2 quarters · filed 2019-03-22 | $2.54M derived: sum of 3 quarters · filed 2019-03-22 | $3.77M 10-K · filed 2019-03-22 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $2.54M derived: sum of 2 quarters · filed 2018-11-14 | $3.77M 10-Q · filed 2018-11-14 | $4.95M derived: sum of 4 quarters · filed 2018-11-14 |
| 2017-06-30 | $2.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $3.77M 10-Q · filed 2018-08-13 | $4.95M derived: sum of 3 quarters · filed 2018-08-13 | $6.11M derived: sum of 4 quarters · filed 2018-08-13 |
| 2017-03-31 | $1.22M 10-Q · filed 2018-05-15 | $2.41M derived: sum of 2 quarters · filed 2018-05-15 | $3.57M derived: sum of 3 quarters · filed 2018-05-15 | $4.70M derived: sum of 4 quarters · filed 2018-05-15 |
| 2016-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $2.34M derived: sum of 2 quarters · filed 2018-04-02 | $3.47M derived: sum of 3 quarters · filed 2018-04-02 | $4.57M 10-K · filed 2018-04-02 |
| 2016-09-30 | $1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $2.28M derived: sum of 2 quarters · filed 2017-11-08 | $3.38M 10-Q · filed 2017-11-08 | $4.54M derived: sum of 4 quarters · filed 2017-11-08 |
| 2016-06-30 | $1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $2.23M 10-Q · filed 2017-08-08 | $3.38M derived: sum of 3 quarters · filed 2017-08-08 | $3.38M derived: sum of 4 quarters · filed 2017-08-08 |
| 2016-03-31 | $1.10M 10-Q · filed 2017-05-10 | $2.25M derived: sum of 2 quarters · filed 2017-05-10 | $2.25M derived: sum of 3 quarters · filed 2017-05-10 | $2.25M derived: sum of 4 quarters · filed 2017-05-10 |
| 2015-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-23 | $1.15M derived: sum of 2 quarters · filed 2017-03-23 | $1.15M derived: sum of 3 quarters · filed 2017-03-23 | $1.15M 10-K · filed 2017-03-23 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $0.00 derived: sum of 2 quarters · filed 2015-11-09 | $0.00 10-Q · filed 2015-11-09 | $12.10K derived: sum of 4 quarters · filed 2016-05-09 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $0.00 10-Q · filed 2015-08-10 | $12.10K derived: sum of 3 quarters · filed 2016-05-09 | $504.33K derived: sum of 4 quarters · filed 2016-05-09 |
| 2015-03-31 | $0.00 10-Q · filed 2016-05-09 | $12.10K derived: sum of 2 quarters · filed 2016-05-09 | $504.33K derived: sum of 3 quarters · filed 2016-05-09 | $1.22M derived: sum of 4 quarters · filed 2016-05-09 |
| 2014-12-31 | $12.10K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $504.33K derived: sum of 2 quarters · filed 2016-03-14 | $1.22M derived: sum of 3 quarters · filed 2016-03-14 | $1.93M 10-K · filed 2016-03-14 |
| 2014-09-30 | $492.23K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $1.21M derived: sum of 2 quarters · filed 2015-11-09 | $1.92M 10-Q · filed 2015-11-09 | $1.92M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-06-30 | $720.30K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $1.43M 10-Q · filed 2015-08-10 | $1.43M derived: sum of 3 quarters · filed 2016-03-14 | $1.43M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-03-31 | $704.82K 10-Q · filed 2015-05-08 | $704.82K derived: sum of 2 quarters · filed 2016-03-14 | $704.82K derived: sum of 3 quarters · filed 2016-03-14 | $704.82K derived: sum of 4 quarters · filed 2016-03-14 |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $0.00 derived: sum of 2 quarters · filed 2016-03-14 | $0.00 derived: sum of 3 quarters · filed 2016-03-14 | $0.00 10-K · filed 2016-03-14 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $0.00 derived: sum of 2 quarters · filed 2014-11-07 | $0.00 10-Q · filed 2014-11-07 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $0.00 10-Q · filed 2014-08-08 | ||
| 2013-03-31 | $0.00 10-Q · filed 2014-05-12 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |